Rosenau, France

Alexandre Simonin

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Alexandre Simonin

Introduction

Alexandre Simonin is a notable inventor based in Rosenau, France. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With a total of 6 patents to his name, Simonin's work has the potential to impact therapeutic approaches in various medical conditions.

Latest Patents

Among his latest patents is an invention titled "Antibodies targeting CD137 and methods of use thereof." This invention relates to an isolated antibody that specifically binds to human CD137, along with pharmaceutical compositions and methods of use. Additionally, he has developed a patent for a "Multispecific antibody comprising CD137 binding domain and PDL1 binding domain." This invention includes a multispecific antibody that contains at least one CD137 binding domain and one PDL1 binding domain, along with related nucleic acids and methods for production.

Career Highlights

Throughout his career, Alexandre Simonin has worked with prominent companies in the biotechnology sector, including Numab Therapeutics AG and Namab Therapeutics AG. His expertise in antibody development has positioned him as a valuable asset in these organizations.

Collaborations

Simonin has collaborated with notable professionals in his field, including Tea Gunde and Christian Hess. These partnerships have likely contributed to the advancement of his innovative projects.

Conclusion

Alexandre Simonin's contributions to biotechnology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…